NEFL and myeloid sarcoma: Serum NfL levels sampled within the first 5 years of MS symptom onset was shown to independently predict long-term worsening EDSS score and risk of developing progressive MS in patients followed longitudinally for 15–26 years (Thebault et al., 2020a).